ConductScience.org, home

Comparison · NCT02385799-sae

Sertraline Active Medication vs Sertraline Liquid Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Sertraline Active Medication vs Sertraline Liquid Placebo: serious adverse events. Trial comparisons, record NCT02385799-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02385799-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03130.005540.157wilson
Risk in group 2000.129wilson
Risk difference, group 1 minus group 20.0313-0.10.157newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more participant with a serious adverse event on Sertraline Active Medication than on Sertraline Liquid Placebo32from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Sertraline Active Medication
Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age at enrollment will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4-5 years at enrollment will be given 5 mg of liquid sertraline once per day for a period of six months.~Sertraline: Active medication
132EG001
Group 2Sertraline Liquid Placebo
The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age at enrollment will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4-5 years at enrollment will be given 5 mg of liquid placebo once per day for a period of six months.~Sertraline Liquid Placebo: Liquid placebo given in parallel to active medication
026EG000

Harm

What it counts
Total, serious adverse events
Time frame
From baseline to follow-up (6 months).

Source ClinicalTrials.gov

Trial

Title
A Trial of Sertraline in Young Children With Autism Spectrum Disorder
NCT number
NCT02385799
Phases
PHASE2
Conditions
Autism Spectrum Disorder
Interventions
Sertraline Liquid Placebo, Sertraline
Lead sponsor
Randi J. Hagerman, MD
Results first posted
2019-05-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02385799-sae